Piergiorgio Malagoli

CHIEF

IRCCS Ospedale San Raffaele

Italy

Research Interests

Explore related searches

Professors in Italy

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Piergiorgio Malagoli is the Chief at IRCCS Policlinico San Donato in Italy. His research focuses primarily on the effectiveness and safety of various treatments for psoriasis and alopecia areata, as evidenced by his recent multicenter real-world studies. He has contributed to significant findings related to the use of brodalumab, bimekizumab, and other therapies in different patient populations, including the elderly and those with complex medical histories.

Articles (10)

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

ITALY

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Piergiorgio Malagoli

Research Interests

Explore related searches

Contact this professor

About

Articles (10)

Baricitinib for the treatment of severe alopecia areata: results from a 52-week multicenter retrospective real-world study

Effectiveness of Brodalumab for the Treatment of Moderate-to-Severe Psoriasis: A Retrospective, Real-World Multicenter Study with a Focus on Obese and Multi-Failure Patients-IL PSO (Italian Landscape Psoriasis).

Effectiveness, speed of action and safety of brodalumab in elderly psoriasis patients: a multicenter real-world study - IL PSO (Italian Landscape Psoriasis).

Safety of interleukin inhibitors in patients with plaque psoriasis and history of neoplasms: a multicenter retrospective study - IL PSO (Italian landscape psoriasis).

Fast Clinical Response of Bimekizumab in Nail Psoriasis: A Retrospective Multicenter 36-Week Real-Life Study.

The Risk of Candidiasis During Treatment with Bimekizumab for the Management of Plaque Psoriasis: A 16-Week Multicenter Real-World Experience - IL PSO (Italian Landscape Psoriasis).

A 3-Year Multicentric Study on Switching from Ustekinumab to Guselkumab in Partial Responders with Psoriasis-IL PSO (Italian Landscape Psoriasis).

Short-term effectiveness and safety of abrocitinib in adults with moderate-to-severe atopic dermatitis: results from a 16-week real-world multicenter retrospective study - il AD (Italian landscape atopic dermatitis).

Secukinumab in the Treatment of Psoriasis: A Narrative Review on Early Treatment and Real-World Evidence.

Efficacy and Safety of bimekizumab in elderly patients: real-world multicenter retrospective study - IL PSO (Italian Landscape Psoriasis).

Collaborators (6)

Claudio Guarneri

Antonio Costanzo

MARINA VENTURINI

Giovanni Paolino

Giovanni Pellacani

Marco Galluzzo

Make your next move.